We collect basic website visitor information on this website and store it in cookies. We also utilize Google Analytics to track page view information to assist us in improving our website.


CONTINUE
eHealth Centre of Excellence
Follow us on:
SIGN UP FOR OUR NEWSLETTER
COMMUNITY PORTAL

 

EMR searches for Respiratory Syncytial Virus (RSV) Immunizations

 

The following EMR searches have been developed by our team in partnership with Ontario Health to help primary care clinicians more efficiently identify patients who would benefit from Respiratory Syncytial Virus (RSV) immunizations. They can be downloaded directly below for PS Suite and OSCAR Pro users, with directions for Accuro QHR users also available. 

 

 

 

TELUS PS Suite

 

​TELUS PS Suite:

 

  1. Download the package: Click here
  2. Unzip the .zip file to your Desktop
  3. Import the search file (.stx file) into PS Suite

 

OSCAR Pro

 

OSCAR Pro: 

 

  1. Download the package: Click here
  2. Import the search file (.xml file) into OSCAR Pro
  

 

Accuro QHR

 

Accuro QHR:

 

  1. Search name: ECE RSV Searches V1

  2. Author: eHealth Centre of Excellence

  3. Date: October 8, 2024

 

 

 

Respiratory Syncytial Virus (RSV) continues to be a major cause of respiratory illness in infants and young children. In the 2022-23 respiratory season, Ontario experienced 3,850 hospitalizations for RSV among children under two, with 538 cases requiring intensive care. Although the previous prevention program utilizing palivizumab (Synagis) was effective, there is a clear need to broaden our efforts to protect more infants, especially those from marginalized and racialized communities.

 

For the 2024-25 RSV season, the Ministry of Health is implementing an expanded prevention program that includes all infants born during and outside the RSV season, as well as children under two with high-risk medical conditions. This will involve transitioning from palivizumab (Synagis) to Nirsevimab (Beyfortus), a monoclonal antibody that offers effective and long-lasting protection with a single dose. This change aims to enhance adherence and broaden the program's impact, particularly in communities with limited healthcare access.

 

Additionally, the RSV vaccine will be available for pregnant individuals to help protect newborns from RSV from birth until six months old. The National Advisory Committee on Immunization (NACI) recommends Beyfortus as the preferred method for infant protection, while the vaccine for pregnant individuals will be provided on a case-by-case basis.

 

More information is available here.

 

If you have any questions about the EMR searches or require any assistance, please contact [email protected].

 

 

.